Bank of New York Mellon Corp increased its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 46.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 19,744 shares of the biotechnology company’s stock after purchasing an additional 6,297 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.10% of AnaptysBio worth $473,000 at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of the stock. Alps Advisors Inc. acquired a new position in AnaptysBio during the second quarter worth approximately $436,000. Schwab Charles Investment Management Inc. increased its position in AnaptysBio by 94.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 19,402 shares of the biotechnology company’s stock worth $465,000 after buying an additional 9,414 shares during the period. Spark Investment Management LLC increased its position in AnaptysBio by 113.5% during the second quarter. Spark Investment Management LLC now owns 74,100 shares of the biotechnology company’s stock worth $1,773,000 after buying an additional 39,400 shares during the period. Bank of America Corp DE acquired a new position in AnaptysBio during the first quarter worth approximately $123,000. Finally, Geode Capital Management LLC acquired a new position in AnaptysBio during the first quarter worth approximately $1,522,000. Hedge funds and other institutional investors own 59.16% of the company’s stock.
Several research analysts have commented on the company. Stifel Nicolaus reissued a “buy” rating and issued a $76.00 target price (up previously from $35.00) on shares of AnaptysBio in a report on Friday, October 13th. Wedbush reissued an “outperform” rating and issued a $75.00 target price (up previously from $37.00) on shares of AnaptysBio in a report on Friday, October 13th. Zacks Investment Research lowered AnaptysBio from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. Robert W. Baird set a $69.00 target price on AnaptysBio and gave the company a “buy” rating in a report on Wednesday, October 11th. Finally, Royal Bank Of Canada boosted their target price on AnaptysBio from $40.00 to $79.00 and gave the company an “outperform” rating in a report on Tuesday, October 10th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. AnaptysBio currently has a consensus rating of “Buy” and an average target price of $71.71.
Shares of AnaptysBio, Inc. (ANAB) opened at 65.49 on Tuesday. The stock has a 50 day moving average price of $47.80 and a 200 day moving average price of $30.95. The stock’s market capitalization is $1.33 billion. AnaptysBio, Inc. has a 12 month low of $15.17 and a 12 month high of $74.00.
AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.29. The company had revenue of $7.00 million during the quarter, compared to analyst estimates of $3.45 million. On average, analysts anticipate that AnaptysBio, Inc. will post ($1.99) EPS for the current fiscal year.
WARNING: “AnaptysBio, Inc. (ANAB) Shares Bought by Bank of New York Mellon Corp” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.com-unik.info/2017/10/31/anaptysbio-inc-anab-shares-bought-by-bank-of-new-york-mellon-corp.html.
In other news, major shareholder Holdings A/S Novo sold 70,706 shares of AnaptysBio stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $23.31, for a total transaction of $1,648,156.86. Following the transaction, the insider now owns 3,009,949 shares in the company, valued at $70,161,911.19. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold 1,096,900 shares of company stock worth $23,321,392 in the last 90 days.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio, Inc. (NASDAQ:ANAB).
What are top analysts saying about AnaptysBio Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AnaptysBio Inc. and related companies.